January 2025 – Page 21

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

4 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

4 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Aortic Valve Insufficiency, Chemistry, Pharmaceutical, Drug Discovery, Immunostimulating conjugate (antigen), Laboratory, Pfizer, Pfizer/, PostEra, Proton Platform, Small Molecule

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.

Aviceda Secures $200M Series C Funding to Advance Ocular Drug AVD-104 into Late-Stage Trials

4 months ago talkbio0Tagged Age related macular degeneration, AVD-104, Genus Aviceda, Geographic Atrophy, late-stage clinical trials, Macular edema due to diabetes mellitus, Series C

Aviceda Therapeutics, AVD-104, Geographic Atrophy, Age-Related Macular Degeneration, Diabetic Macular Edema, Series C Funding, Late-Stage Clinical Trials

Immuneering’s Pancreatic Cancer Therapy Shows Promising Results in Phase 2a Trial, Stock Surges 55%

4 months ago talkbio0Tagged Cancer Therapeutic Procedure, Clinical Trials, IMM-1, Immuneering, Inhibitor, MEK, Pancreatic carcinoma, Phase 2a Trial, surge

Immuneering, IMM-1-104, Pancreatic Cancer, Phase 2a Trial, MEK Inhibitor, Cancer Therapy, Clinical Trial Results, Stock Surge

XyloCor Therapeutics Secures $67.5 Million in Series B Funding to Advance Cardiovascular Gene Therapy

4 months ago talkbio0Tagged CABG, cardiovascular gene therapy, Clinical Trials, Refractory angina, Series B, XyloCor Therapeutics

XyloCor Therapeutics, Series B funding, cardiovascular gene therapy, XC001, refractory angina, CABG, clinical trials

Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing

4 months ago talkbio0Tagged Clinical Trials, dosing, GLP-1RA, MET-097i, Metsera, monthly, Obesity

Metsera, GLP-1RA, MET-097i, obesity treatment, monthly dosing, weight loss, clinical trials

Capsida and AbbVie’s Gene Therapy Collaboration Yields Promising Results for Eye Diseases

4 months ago talkbio0Tagged AbbVie, Capsida Biotherapeutics, Dependovirus, gene therapy, genetic medicines, Ophthalmology specialty, strategic collaboration

Capsida Biotherapeutics, AbbVie, gene therapy, eye diseases, strategic collaboration, adeno-associated virus (AAV) engineering platform, ophthalmology, genetic medicines.

FDA Introduces New Guidance on AI for Drug Approval Submissions in 2025

4 months ago talkbio0Tagged Advice, Aortic Valve Insufficiency, Artificial Intelligence, Drug Approval, Drug Development, Medical Devices, regulatory decision-making, United States Food and Drug Administration

FDA, AI, drug approval, guidance, regulatory decision-making, medical devices, artificial intelligence, drug development

FDA Advisory Panels: Activity Levels Normalize After 2023 Surge

4 months ago talkbio0Tagged Advisory Committees, Advisory Panels, Meetings, regulatory, United States Food and Drug Administration

FDA advisory panels, adcomms, regulatory changes, advisory committee meetings

Denali Therapeutics’ ALS Drug DNL343 Fails to Meet Primary Efficacy Endpoints in Phase 2/3 HEALEY ALS Platform Trial

4 months ago talkbio0Tagged Agonist, Amyotrophic Lateral Sclerosis, Clinical trial failure, Denali, DNL343, Eukaryotic Initiation Factor-2B, HEALEY, Neurodegenerative Disorders

Denali Therapeutics, DNL343, ALS (Amyotrophic Lateral Sclerosis), HEALEY ALS Platform Trial, eIF2B agonist, Clinical trial failure, Neurodegenerative diseases